Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4138735 | Seminars in Diagnostic Pathology | 2011 | 16 Pages |
Abstract
Primary malignant bone tumors are rare sarcomas with an estimated frequency of about 2900 new cases per year; they constitute less than 0.2% of all cancers diagnosed in the United States. The diagnosis and management of these neoplasms require a team approach, which includes orthopaedic surgeons, radiologists, pathologists, and oncologists. With this approach and current treatment modalities, the 5-year survival for the most common malignant bone tumors, osteosarcoma and Ewing sarcoma, are 70% and 60%, respectively. This review will summarize recent developments and advances in molecular pathogenesis of the more common primary malignant bone neoplasms.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
Meera Hameed, Howard Dorfman,